Collecting blood samples from patients with active non-small cell lung cancer
Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research
This study is collecting blood samples from people with active non-small cell lung cancer to see how their immune system responds and to help find new treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Sanguine Biosciences Industry-sponsored |
| Locations | 1 site (Waltham, Massachusetts) |
| Trial ID | NCT05669105 on ClinicalTrials.gov |
What this trial studies
This study aims to collect whole blood samples from individuals diagnosed with active non-small cell lung cancer (NSCLC) to investigate the immune response associated with the disease. By analyzing these samples, researchers hope to gain insights that could lead to the development of new treatments and therapies for lung cancer. Participants must provide informed consent and have relevant tissue biomarker data available. The study focuses on patients with adenocarcinoma or squamous cell carcinoma at any stage of the disease.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 100 who have been diagnosed with active non-small cell lung cancer and have associated tissue biomarker data.
Not a fit: Patients who are currently in remission or have a history of certain infectious diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments and therapies for patients with non-small cell lung cancer.
How similar studies have performed: While this approach is observational and focuses on biospecimen collection, similar studies have shown promise in understanding cancer biology and developing targeted therapies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants willing and able to provide written informed consent * Participants are willing and able to provide appropriate photo identification * Participant's age 18 - 100 years old * Participants diagnosed with active non-small cell lung cancer (Adenocarcinoma or Squamous Cell only. All stages are acceptable.) * Participants must have associated tissue biomarker data (EFGR and MET mutations) in their medical records Exclusion Criteria: * Participants who are pregnant or nursing * Participants with a known history of HIV, hepatitis, or other infectious diseases * Participants who have taken an investigational product in the last 30 days * Participants who have experienced excess blood loss, including blood donation defined as 250 mL in the last month or 500 mL in the previous two months * Participants currently enrolled in a clinical trial * Participants currently in remission
Where this trial is running
Waltham, Massachusetts
- Sanguine Biosciences — Waltham, Massachusetts, United States (Recruiting)
Study contacts
- Study coordinator: Thomas Goslin
- Email: tgoslin@sanguinebio.com
- Phone: (818) 583-8844
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.